GET DAILY SIGNALSWhy Is Twist Bioscience (TWST) Stock Down -11.90% Today?
Key Takeaways
- TWST shares fell roughly 11.90% to $134.60 in Monday's session, down from Friday's closing level of $152.78.
- The decline extended last week's selloff, driven by continued rotation out of high-multiple, AI-linked genomics and growth names.
- The stock broke below key short-term moving averages, triggering technical selling after a more than fourfold rally over the past year.
- Sector pressure from life-science tools and genomics peers, including fallout from Illumina's recent revenue miss, added to the weakness.
- Investors are now focused on the company's fiscal fourth-quarter results, due November 12, 2026.
- For additional detail on valuation and analyst views, explore Price Targets, Earnings, and Forecast pages.
- Track the strongest automated strategies under current market conditions by visiting Trending AI Robots.
Opening Summary
Twist Bioscience Corporation (TWST), the South San Francisco-based synthetic biology company that manufactures synthetic DNA on a proprietary silicon platform, saw its shares slide sharply on Monday. The stock fell about 11.90% to $134.60, down from a prior-session close of $152.78. The move extended last Friday's double-digit decline, confirming that selling pressure across AI-linked genomics and life-science tools names remains intense even with no fresh company-specific news released during the session.
Catalyst Breakdown
Rotation Out of High-Multiple AI-Linked Growth Names
The most immediate driver behind the selloff appears to be a continued rotation away from richly valued, AI-adjacent growth stocks. TWST had more than quadrupled over the trailing twelve months as investors priced in enthusiasm around AI-enabled drug discovery and the company's role in AI-guided biology. That rally left the stock trading at an elevated price-to-sales multiple well above its historical average, making it vulnerable when sentiment toward the broader AI-growth complex cooled.
Technical Breakdown and Profit-Taking
Technically, the decline pushed shares through their 50-day moving average and other short-term trend indicators, a development that can trigger systematic and momentum-driven selling. After a rapid climb through the $130–$178 range in October, the stock has now surrendered much of that gain, with momentum gauges such as MACD and stochastic oscillators turning lower. The move is consistent with profit-taking in a name that had delivered enormous gains to holders over the prior year.
Sector and Peer Pressure
Weakness in the broader genomics and life-science tools complex compounded the move. Illumina's recent third-quarter revenue shortfall set a cautious tone across the sector, and peers such as 10x Genomics traded lower in sympathy. Because TWST is frequently held by the same investors who own genomics and sequencing names, the stock has increasingly moved in tandem with sector sentiment rather than purely on its own fundamentals.
Valuation Concerns Ahead of Earnings
With fiscal fourth-quarter and full-year results scheduled for November 12, 2026, some investors appeared to de-risk into the print. The company remains unprofitable on a GAAP basis, and its valuation has drawn scrutiny from analysts who argue the recent surge reflected multiple expansion tied to AI enthusiasm rather than fundamental earnings power alone.
Market Context and Trading Activity
Trading activity reflected conviction behind the decline, with volume running well above the stock's roughly 2.3 million-share average in recent sessions. The selloff diverged from any broad market strength and instead aligned with weakness across AI-linked and life-science growth stocks, which have been under pressure as investors reassess valuations in the sector. The break below prior technical support levels reinforced the negative bias and left the stock testing levels last seen during the early stages of its autumn advance.
What Comes Next for TWST
The primary catalyst on the horizon is the company's fiscal 2026 fourth-quarter report on November 12, 2026. Investors will be watching revenue growth, gross-margin trends, the path to adjusted EBITDA breakeven, and any update on AI-enabled drug-discovery orders, which management has guided to grow at a triple-digit percentage pace. Sector developments in life-science tools and the broader tone of AI-linked growth stocks will also influence near-term direction. Key risks include continued multiple compression, slower-than-expected progress toward profitability, and the possibility that sector sentiment remains weak into the earnings release.
Trending AI Robots
Tickeron's Trending AI Robots page highlights the platform's strongest-performing automated trading strategies under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the top performers are curated in this section. The bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing traders to explore approaches that align with their own objectives. Explore the Trending AI Robots page to see which strategies are leading the market today.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for TWST turns positive, indicating new upward trend
TWST saw its Momentum Indicator move above the 0 level on October 27, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 77 similar instances where the indicator turned positive. In 69 of the 77 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for TWST just turned positive on October 28, 2026. Looking at past instances where TWST's MACD turned positive, the stock continued to rise in 39 of 45 cases over the following month. The odds of a continued upward trend are 87%.
Following a +19.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where TWST advanced for three days, in 235 of 293 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Aroon Indicator entered an Uptrend today. In 181 of 228 cases where TWST Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.
Bearish Trend Analysis
The 10-day RSI Indicator for TWST moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 45 similar instances where the indicator moved out of overbought territory. In 39 of the 45 cases, the stock moved lower in the following days. This puts the odds of a move lower at 87%.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
TWST moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for TWST crossed bearishly below the 50-day moving average on October 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TWST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
TWST broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (22.725) is normal, around the industry mean (3.162). TWST has a moderately low P/E Ratio (-68.511) as compared to the industry average of (-1.064). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.622) among similar stocks. P/S Ratio (20.243) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. TWST’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 44 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 71 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TWST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
What is Market Segmentation? A Vital Marketing Strategy
What is the Investment Company Act of 1940?
How is Conservatorship Defined? What are its Mechanisms, Classifications, and Alternatives?
What Are Financial Quotations and Why Are They Crucial for Investors?
Selecting AI Trading Bots: Tickeron Releases a Step-by-Step Guide
General Information
a developer of proprietary semiconductor-based synthetic DNA manufacturing process
Industry Biotechnology
Advertisement